Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Phase 3 trial of inhaled ambroxol hydrochloride versus placebo for sticky sputum symptoms in adults with lower respiratory tract infection
ChiCTR2000032521Phase 3Recruiting
- Sponsor
- Chongqing General Hospital
- Start
- May 2020
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 3, randomised, double-blind trial of ambroxol in pulmonary infection, chronic bronchitis (CB), pneumonia and 1 more (2 arms), sponsored by Chongqing General Hospital. Primary endpoint: Sputum trait score-time area under the curve (AUC). Started May 2020; status: recruiting.
02
Drugs
ambroxol
03
Conditions
pulmonary infectionchronic bronchitis (CB)pneumoniachronic obstructive pulmonary disease (COPD)
Beyond the preview
Go deeper on ChiCTR2000032521.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ChiCTR2000032521.